KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Net Cash Flow (2016 - 2025)

Jazz Pharmaceuticals has reported Net Cash Flow over the past 16 years, most recently at $65.8 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $65.8 million for Q4 2025, down 66.6% from a year ago — trailing twelve months through Dec 2025 was -$1.0 billion (down 213.13% YoY), and the annual figure for FY2025 was -$1.0 billion, down 213.13%.
  • Net Cash Flow for Q4 2025 was $65.8 million at Jazz Pharmaceuticals, down from $136.0 million in the prior quarter.
  • Over the last five years, Net Cash Flow for JAZZ hit a ceiling of $1.0 billion in Q1 2021 and a floor of -$1.2 billion in Q2 2021.
  • Median Net Cash Flow over the past 5 years was $60.1 million (2023), compared with a mean of $16.9 million.
  • Peak annual rise in Net Cash Flow hit 1495.57% in 2021, while the deepest fall reached 1538.39% in 2021.
  • Jazz Pharmaceuticals' Net Cash Flow stood at -$78.9 million in 2021, then skyrocketed by 147.11% to $37.2 million in 2022, then skyrocketed by 353.98% to $168.8 million in 2023, then increased by 16.7% to $197.0 million in 2024, then plummeted by 66.6% to $65.8 million in 2025.
  • The last three reported values for Net Cash Flow were $65.8 million (Q4 2025), $136.0 million (Q3 2025), and -$676.7 million (Q2 2025) per Business Quant data.